{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-052167","form_type":"8-K","ticker":"SXTP","cik":"0001946563","company_name":"60 DEGREES PHARMACEUTICALS, INC.","filed_at":"2024-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.277864+00:00","generated_at":"2026-06-01T04:55:47.928616+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"60 Degrees Pharmaceuticals receives FDA orphan drug designation for tafenoquine to treat acute babesiosis","bullets":["FDA granted orphan drug designation for tafenoquine for acute babesiosis; company qualifies for market exclusivity, tax credits, and exemption from certain FDA filing fees.","Company entered agreement with Tufts Medical Center for first clinical trial in human babesiosis patients; recruitment starts June 13, 2024, with at least 24 hospitalized patients.","Babesiosis is transmitted by deer ticks; up to 47,600 of ~476,000 annual Lyme patients may be co-infected with Babesia."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-052167","json":"https://secwatch.observer/filing/0001213900-24-052167.json","markdown":"https://secwatch.observer/filing/0001213900-24-052167.md","text":"https://secwatch.observer/filing/0001213900-24-052167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024052167/0001213900-24-052167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024052167/ea020775201-8k_60degrees.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:55:47.928616+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}